exercise of sublicence nears completion Graham Dowland, Imugene's Managing Director commented, "The signing of these contracts confirms that the biotherapeutic productivity enhancer is now ready for external evaluation and validation. Following Merial's evaluation and potential exercise of their sublicense option, a global registration process will be initiated with Imugene retaining manufacturing and distribution rights for this product in Australia, New Zealand and Japan."
outbreak in china, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.002(3.51%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.9¢ | 5.5¢ | $1.012M | 18.02M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 590122 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 1408449 | 3 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |